Pharmacology with Entrepreneurship

Pharmacology is the science of how drugs interact with living systems, asking where they act in the body, what effects they produce, how they are metabolised and excreted, and what toxic effects they may cause. Understanding these questions requires working across scales, from the single molecule and its binding to a receptor protein through to the physiological response of whole tissues, organs and organisms. Pharmacology is foundational to the development of new medicines, the safe prescribing of existing ones, and the understanding of both therapeutic benefit and adverse effects.

Adding entrepreneurship to this foundation creates a distinctive combination that bridges rigorous scientific training with the commercial and organisational thinking needed to bring discoveries to patients.

At the University of Manchester, this four-year full-time programme includes a foundation year and explores drug actions on living systems at every level of biological organisation. You will study pharmacokinetics and pharmacodynamics, molecular pharmacology, neuropharmacology, cardiovascular and other systems pharmacology, drug toxicology and the regulatory pathway from laboratory discovery to clinical application. The entrepreneurship strand develops your understanding of innovation management, intellectual property, venture creation and the ecosystem of the pharmaceutical and biotech industries, giving you the commercial perspective that translates scientific knowledge into real-world impact.

Graduates from this programme are well placed for careers in pharmaceutical companies, biotechnology firms, clinical trials organisations, regulatory agencies, hospital pharmacy and academic research. The entrepreneurship dimension opens additional paths in health technology start-ups, investment, science consultancy and innovation policy. Many graduates continue to postgraduate study in pharmacology, drug discovery, clinical pharmacology or biomedical science, and some pursue PhD research in areas ranging from cancer pharmacology to drug safety.